Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia

São Paulo 03102-002

0 studies enrolling now · 3 studies all time

What they study most

Multiple Myeloma, Urothelial Cancer

Studies at this site

• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Running, not enrolling
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy — Completed
• Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab — Stopped early